Join
Live feed
·
PRReleasevia Quantisnow
Intra-Cellular Therapies Inc. logo

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features

ByQuantisnow·Wall Street's wire, on your screen.
ITCI· Intra-Cellular Therapies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ITCI (Intra-Cellular Therapies Inc.) and more on Quantisnow.

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features | Quantisnow